Skip to main content

Articles

Page 79 of 108

  1. There is sufficient evidence that blood group related Lewis antigens are tumour-associated molecules. The Lewisy and Lewisb antigens are complex carbohydrates that are over-expressed by breast, lung, colon and ov...

    Authors: Zahra Madjd, Tina Parsons, Nicholas FS Watson, Ian Spendlove, Ian Ellis and Lindy G Durrant
    Citation: Breast Cancer Research 2005 7:R780
  2. Unclassified variants (UVs) of unknown clinical significance are frequently detected in the BRCA2 gene. In this study, we have investigated the potential pathogenic relevance of the recurrent UV S384F (BRCA2, exo...

    Authors: B Wappenschmidt, R Fimmers, K Rhiem, M Brosig, E Wardelmann, A Meindl, N Arnold, P Mallmann and RK Schmutzler
    Citation: Breast Cancer Research 2005 7:R775
  3. A loss of p53 function resulting from mutation is prevalent in human cancers. Thus, restoration of p53 function to mutant p53 using small compounds has been extensively studied for cancer therapy. We previousl...

    Authors: Abdur Rehman, Manpreet S Chahal, Xiaoting Tang, James E Bruce, Yves Pommier and Sayed S Daoud
    Citation: Breast Cancer Research 2005 7:R765
  4. Endocrine therapy is the most important treatment option for women with hormone-receptor-positive breast cancer. The potential mechanisms for endocrine resistance involve estrogen receptor (ER)-coregulatory pr...

    Authors: Hiroko Yamashita, Mariko Nishio, Shunzo Kobayashi, Yoshiaki Ando, Hiroshi Sugiura, Zhenhuan Zhang, Maho Hamaguchi, Keiko Mita, Yoshitaka Fujii and Hirotaka Iwase
    Citation: Breast Cancer Research 2005 7:R753
  5. Estrogen and its receptor (ER) are critical for development and progression of breast cancer. This pathway is targeted by endocrine therapies that either block ER functions or deplete ER's estrogen ligand. Whi...

    Authors: Rachel Schiff and C Kent Osborne
    Citation: Breast Cancer Research 2005 7:205
  6. Intraductal approaches encompass procedures and technologies that are designed to access and interrogate the ductal–alveolar systems of the human breast, and include nipple aspiration, ductal lavage, random pe...

    Authors: Bonnie L King, Susan M Love, Susan Rochman and Julian A Kim
    Citation: Breast Cancer Research 2005 7:198
  7. MBD2, the gene encoding methyl-CpG-binding domain (MBD)2, is a major methylation related gene and functions as a transcriptional repressor that can specifically bind to the methylated regions of other genes. MBD2...

    Authors: Yong Zhu, Heather N Brown, Yawei Zhang, Theodore R Holford and Tongzhang Zheng
    Citation: Breast Cancer Research 2005 7:R745
  8. Loss of the cell-cycle inhibitory protein p27Kip1 is associated with a poor prognosis in breast cancer. The decrease in the levels of this protein is the result of increased proteasome-dependent degradation, medi...

    Authors: Merav Slotky, Ma'anit Shapira, Ofer Ben-Izhak, Shai Linn, Boris Futerman, Medy Tsalic and Dan D Hershko
    Citation: Breast Cancer Research 2005 7:R737
  9. Germline mutations in the BRCA1 and BRCA2 genes have been shown to account for the majority of hereditary breast and ovarian cancers. The purpose of our study was to estimate the incidence and spectrum of pathoge...

    Authors: Petr Pohlreich, Michal Zikan, Jana Stribrna, Zdenek Kleibl, Marketa Janatova, Jaroslav Kotlas, Jana Zidovska, Jan Novotny, Lubos Petruzelka, Csilla Szabo and Bohuslav Matous
    Citation: Breast Cancer Research 2005 7:R728
  10. The mammary gland consists of an extensively branched ductal network contained within a distinctive basement membrane and encompassed by a stromal compartment. During lactation, production of milk depends on t...

    Authors: Melissa C Adriance, Jamie L Inman, Ole W Petersen and Mina J Bissell
    Citation: Breast Cancer Research 2005 7:190
  11. Immunotoxins are hybrid molecules that generally consist of a toxin coupled with a tumor-specific antibody or antibody fragment that is intended to target and concentrate the toxin within the tumor tissue. The...

    Authors: Davorka Messmer and Thomas J Kipps
    Citation: Breast Cancer Research 2005 7:184
  12. The present study was conducted to investigate if chromosome band 3p14 is of any pathogenic significance in the malignant process of breast cancer. Genetic studies have implicated a tumour suppressor gene on c...

    Authors: Ingrid Ljuslinder, Beatrice Malmer, Irina Golovleva, Marcus Thomasson, Kjell Grankvist, Thomas Höckenström, Stefan Emdin, Yvonne Jonsson, Håkan Hedman and Roger Henriksson
    Citation: Breast Cancer Research 2005 7:R719

    The Erratum to this article has been published in Breast Cancer Research 2006 8:405

  13. Co-expression of several receptor tyrosine kinases (RTKs), including erbB2 and erbB3, is frequently identified in breast cancers. A member of the RTK family, the kinase-deficient erbB3 can activate downstream ...

    Authors: Aeree Kim, Bolin Liu, Dalia Ordonez-Ercan, Kathy M Alvarez, Lynn D Jones, Christine McKimmey, Susan M Edgerton, XiaoHe Yang and Ann D Thor
    Citation: Breast Cancer Research 2005 7:R708
  14. Se-methylselenocysteine (MSC), a naturally occurring selenium compound, is a promising chemopreventive agent against in vivo and in vitro models of carcinogen-induced mouse and rat mammary tumorigenesis. We have ...

    Authors: Emmanual Unni, Dimpy Koul, Wai-Kwan Alfred Yung and Raghu Sinha
    Citation: Breast Cancer Research 2005 7:R699
  15. Radiotherapy outcomes might be further improved by a greater understanding of the individual variations in normal tissue reactions that determine tolerance. Most published studies on radiation toxicity have be...

    Authors: Escarlata López, Rosario Guerrero, Maria Isabel Núñez, Rosario del Moral, Mercedes Villalobos, Joaquina Martínez-Galán, Maria Teresa Valenzuela, José Antonio Muñoz-Gámez, Francisco Javier Oliver, David Martín-Oliva and José Mariano Ruiz de Almodóvar
    Citation: Breast Cancer Research 2005 7:R690
  16. The aim of the study was to evaluate the activity of a combination of doxorubicin (Dox), paclitaxel (Pacl) and 5-fluorouracil (5-FU), to define the most effective schedule, and to investigate the mechanisms of...

    Authors: Wainer Zoli, Paola Ulivi, Anna Tesei, Francesco Fabbri, Marco Rosetti, Roberta Maltoni, Donata Casadei Giunchi, Luca Ricotti, Giovanni Brigliadori, Ivan Vannini and Dino Amadori
    Citation: Breast Cancer Research 2005 7:R681
  17. Early stopping of clinical trials in favour of a new treatment creates ethical and scientific difficulties, which are different from those associated with early stopping due to toxicity or futility. Two major ...

    Authors: Jack Cuzick, Anthony Howell and John Forbes
    Citation: Breast Cancer Research 2005 7:181

Annual Journal Metrics

  • 2022 Citation Impact
    7.4 - 2-year Impact Factor
    7.4 - 5-year Impact Factor
    1.764 - SNIP (Source Normalized Impact per Paper)
    2.408 - SJR (SCImago Journal Rank)

    2023 Speed
    20 days submission to first editorial decision for all manuscripts (Median)
    129 days submission to accept (Median)

    2023 Usage 
    2,432,781 downloads
    1,561 Altmetric mentions